Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Key Stats

• Today's Range: $3.11 to $3.19
• 50-Day Range: $2.84 to $3.62
• 52-Week Range: $2.20 to $5.58
• Volume: 11,979 shs
• Average Volume: 6,665 shs
• Market Capitalization: $86.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Strong Buy

EPRX Stock Analysis - Frequently Asked Questions

How have EPRX shares performed this year?

Eupraxia Pharmaceuticals' stock was trading at $3.17 on January 1st, 2025. Since then, EPRX shares have increased by 0.0% and is now trading at $3.17.
View the best growth stocks for 2025 here.

How were Eupraxia Pharmaceuticals' earnings last quarter?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.17) earnings per share (EPS) for the quarter.

How do I buy shares of Eupraxia Pharmaceuticals?

Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eupraxia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eupraxia Pharmaceuticals investors own include Aeterna Zentaris (AEZS), BlackBerry (BB), Bausch Health Companies (BHC), Bitfarms (BITF), Ballard Power Systems (BLDP), Cardiol Therapeutics (CRDL) and Fury Gold Mines (FURY).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EPRX
• Previous Symbol: NASDAQ:EPRX
• CUSIP: N/A
• CIK: 1581178
• Web: www.eupraxiapharma.com
• Phone: 250-590-3968
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +183.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-28,220,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -219.64%
• Return on Assets: -96.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.17
• Quick Ratio: 4.17

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 105.67

Miscellaneous

• Outstanding Shares: 27,280,000
• Free Float: N/A
• Market Cap: $86.48 million
• Optionable: N/A
• Beta: N/A